证券代码：301331 证券简称：恩威医药 公告编号：2025-056 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 恩威医药股份有限公司（以下简称"公司"、"本公司"）近日接到控股股 东成都恩威投资（集团）有限公司（以下简称"恩威集团"）函告，获悉恩威集 团所持本公司的部分股份被办理了解除质押。恩威集团为公司控股股东，持有公 司 29,733,200 股，占公司总股本的 28.90%。具体事项如下： 2、股东股份累计质押情况 1 股东 名称 是否为控股股东 或第一大股东及 其一致行动人 本次解除 质押数量 （股） 占其所 持股份 比例 占公司 总股本 比例 质押 起始 日 质押 解除 日 质权人 质押 用途 恩威 集团 是 4,000,000 13.45% 3.89% 2025 /8/26 2025 /12/5 浙江香 溢元泰 典当有 限责任 公司 自身 生产 经营 合计 - 4,000,000 - 3.89% - - - - 1、本次股东股份解除质押基本情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 股东名称 ...

Group 1 - The core viewpoint of the news is that Enwei Pharmaceutical has shown a mixed performance in terms of financing activities and stockholder metrics, with significant growth in revenue and net profit year-on-year [1][2][3] Group 2 - As of December 1, Enwei Pharmaceutical's stock price increased by 1.84%, with a trading volume of 27.19 million yuan [1] - The financing buy-in amount on December 1 was 1.66 million yuan, while the financing repayment was 3.10 million yuan, resulting in a net financing buy-in of -1.44 million yuan [1] - The total balance of margin trading for Enwei Pharmaceutical reached 100 million yuan, accounting for 3.26% of its circulating market value, which is above the 80th percentile of the past year [1] - The company has not engaged in any short selling activities on December 1, with a short selling balance of 0 [1] - Enwei Pharmaceutical's main business includes the research, production, and sales of traditional Chinese medicine and chemical drugs, focusing on gynecological products, pediatric medications, and respiratory system drugs [1] - For the period from January to September 2025, Enwei Pharmaceutical achieved an operating income of 637 million yuan, representing a year-on-year growth of 13.65% [2] - The net profit attributable to the parent company for the same period was 36.58 million yuan, showing a significant year-on-year increase of 66.13% [2] - As of September 30, 2025, the number of shareholders for Enwei Pharmaceutical was 6,340, a decrease of 13.72% from the previous period [2] - The average circulating shares per person increased to 16,198 shares, up by 261.71% from the previous period [2] - Enwei Pharmaceutical has distributed a total of 185 million yuan in dividends since its A-share listing [3] - The top ten circulating shareholders saw a change, with the Rongtong Health Industry Flexible Allocation Mixed A/B fund exiting the list [3]

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Core Viewpoint - Enwei Pharmaceutical's subsidiary, Henan Xinxin Pharmaceutical Co., Ltd., has recently obtained a renewed drug production license, which includes adjustments to production address and scope, as well as new contract manufacturing arrangements [2] Group 1: License and Production Details - The new production license allows Xinxin Pharmaceutical to produce various dosage forms, including tablets, granules, and pills, at its facility located at No. 56, Longhai Middle Road, Zhengzhou [2] - The license specifies contract manufacturing arrangements with Shoulu Pharmaceutical Co., Ltd. in Chengdu, Sichuan Province, for producing specific products such as Qingre Jiedu Oral Liquid [2] - Xinxin Pharmaceutical has been authorized to contract Shoulu Pharmaceutical for the production of two products: Ren Shen Yang Rong Gao and Yi Fei Jian Pi Granules, which have completed the necessary licensing changes [2] Group 2: Impact on Company Operations - The gradual implementation of contract manufacturing is expected to optimize the product structure, increase production capacity, reduce manufacturing costs, and meet market demand [2] - This development is anticipated to have a positive impact on the company's revenue and profit metrics [2] Group 3: Financial Performance - In the first three quarters, Enwei Pharmaceutical achieved total revenue of 637 million yuan, representing a year-on-year increase of 13.65% [2] - The net profit attributable to shareholders reached 36.58 million yuan, marking a year-on-year growth of 66.13% [2]

Group 1: Share Pledge Announcement - The announcement details the share pledge and release of shares by major shareholders of Enwei Pharmaceutical, including Chengdu Enwei Investment Group, Chengdu Ruijin Heng Enterprise Management, and Chengdu Jiewei Enterprise Management [1][2] - Chengdu Enwei Investment Group holds 29,733,200 shares, accounting for 28.90% of the total share capital, while Chengdu Ruijin Heng and Chengdu Jiewei hold 12,884,140 shares (12.52%) and 14,103,036 shares (13.71%) respectively [1] - The total pledged shares exceed 50% of the shares held by these shareholders, with 14,140,836 shares maturing in the next six months, representing 19.89% of their holdings and 13.74% of the total share capital, with a financing balance of 160 million yuan [1][2] Group 2: Financial Health and Impact - The shareholders have a good credit and financial status, ensuring their ability to repay the pledged shares without risk of forced liquidation or transfer [4] - The share pledge does not affect the company's operations, governance, or financial stability, and there are no significant obligations related to major asset restructuring [2][4] Group 3: Drug Production License Announcement - Enwei Pharmaceutical's wholly-owned subsidiary, Henan Xinxin Pharmaceutical, has obtained a renewed Drug Production License, valid until December 31, 2025 [6][7] - The license allows for the production of various forms of medication, including tablets, granules, and syrups, with specific products listed under the license [6][7] - The completion of the production address change and related approvals is necessary before the new products can be launched, which is expected to enhance the company's product structure and profitability [7]

Group 1 - The company Enwei Pharmaceutical (301331.SZ) announced that its wholly-owned subsidiary, Henan Xinxin Pharmaceutical Co., Ltd., has recently obtained a renewed "Drug Production License" from the drug regulatory authority [1] - Two products, Ren Shen Yang Rong Gao and Yi Fei Jian Pi Granules, have completed the renewal of their production licenses for entrusted and commissioned production [1] - Henan Xinxin Pharmaceutical Co., Ltd. still needs to complete the filing for changes in production address and related changes before it can commence production [1]

证券代码：301331 证券简称：恩威医药 公告编号：2025-054 恩威医药股份有限公司 关于全资子公司取得换发的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称"公司"）全资子公司河南信心药业有限公司 （以下简称：信心药业）于近日取得了药品监管部门换发的《药品生产许可证》，现 将有关情况公告如下： 一、换发的《药品生产许可证》基本信息 企业名称：河南信心药业有限公司 注册地址：郑州市二七区嵩山南路 81 号嵩山园区综合楼南楼第五层楼 社会信用代码：91410100170007221L 法定代表人：庄严 企业负责人：陈世超 质量负责人：王珏 有效期至：2025 年 12 月 31 日 编 号：豫 20150079 分类码：AzBz 生产地址和生产范围： 郑州市陇海中路 56 号：片剂，颗粒剂，散剂，丸剂(大蜜丸、水蜜丸、水丸、浓 缩丸、蜡丸)，合剂(口服液)，糖浆剂，煎膏剂(含中药前处理及提取)***四川省成都市 双流区双华路三段 458 号(受托生产企业为四川恩威制药有限公司)前处理车间中药前 处理 ...

证券代码：301331 证券简称：恩威医药 公告编号：2025-055 恩威医药股份有限公司 关于控股股东、持股 5%以上股东部分股份质押及解除质押 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 1 股 东 名 称 是否 为控 股股 东或 第一 大股 东及 其一 致行 动人 本次质押 数量（股） 占其 所持 股份 比例 占公 司总 股本 比例 是否 为限 售股 （如 是， 注明 限售 类 型） 是否 为补 充质 押 质押起 始日 质押到 期日 质权 人 质 押 用 途 恩 威 集 团 是 1,500,00 0 5.04% 1.46% 无限 售流 通股 否 2025/11 /25 申请解 除质押 登记日 浙商 金汇 信托 股份 有限 自 身 生 产 经 1、本次股东股份质押基本情况 恩威医药股份有限公司（以下简称"公司"、"本公司"）近日接到控股股 东成都恩威投资（集团）有限公司（以下简称"恩威集团"）、持股 5%以上股 东成都瑞进恒企业管理有限公司（以下简称"成都瑞进恒"）、成都杰威企业管 理有限公司（以下简称"成都杰威"） ...

证券日报网讯恩威医药11月21日在互动平台回答投资者提问时表示，公司一直以来重视市值管理，在专 注主业经营的基础上持续提升企业内在价值，注重回报，积极开展关系管理工作。 （文章来源：证券日报） ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股东股份质押基本情况 恩威医药股份有限公司（以下简称"公司"、"本公司"）近日接到控股股东成都恩威投资（集团）有限公 司（以下简称"恩威集团"）函告，获悉恩威集团所持本公司的部分股份被办理了质押。恩威集团为公司 控股股东，截至2025年11月20日，持有公司股份29,733,200股，占公司总股本的28.90%。具体事项如 下： 1、本次股份质押不用于满足上市公司生产经营需求； 2、恩威集团及其一致行动人未来半年内到期的累计质押股份数量为24,500,836 股，占其所持公司股份 的34.46%，占公司总股本的23.81%，对应融资余额为24,700万元；未来一年内到期的累计质押股份数量 为50,940,836 股，占其所持公司股份的71.65%，占公司总股本的49.51%，对应融资余额为51,900万元。 公司及其一致行动人具备相应的资金偿还能力，还款资金来源为自有及自筹资金； 3、截至本公告披露日，上述股东及其一致行动人不存在非经营性资金占用、违规担保等侵 ...